医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Company Profile for Shandong Fontacea Pharmaceutical Co. Ltd.

2019年12月18日 AM02:24
このエントリーをはてなブックマークに追加


 

About Shandong Fontacea Pharmaceutical Co. Ltd. Fontacea is a biopharmaceutical company dedicated to research, development and commercialization of innovative medicines for the global market, conveniently located in the Jining Hightech Zone, China, with a biopharmaceutical technology research & development center in Jinan. Since its inception, it is dedicated to developing medicines for patients with respiratory diseases, inflammatory & autoimmune diseases, and cancers. Its vision is to become a fully integrated biopharmaceutical company that, through both internal research and development and in-licensing/partnership programs, discovers, develops, and commercializes novel medical products in worldwide. For more information about Fontacea visit http://www.fontaceapharma.com.

 

Company:

 

Shandong Fontacea Pharmaceutical Co. Ltd.

 

 

 

Headquarters Address:

 

1301, South Building 9, Shuntai Plaza

 

 

Shunhua Road,

 

 

Jinan 20000

 

 

China

 

 

 

Main Telephone:

 

+86 0531-82352267

 

 

 

Website:

 

http://www.fontaceapharma.com/en

 

 

 

Type of Organization:

 

Private

 

 

 

Industry:

 

Biotechnology

 

 

 

Key Executives:

 

CEO: Yanliang Chu

 

 

Vice General Manager: Xiaoli Chai

 

 

VP, R&D: Liang Li

 

 

 

General Enquiries

 

 

Contact:

 

Jingwen Liu

Email:

 

jingwenliu@fontacea.com

 

 

 

Public Relations

 

 

Contact:

 

Xiaoli Chai

Phone:

 

+8615069040521

Email:

 

evachai@fontacea.com

 

 

 

US contact

 

 

Contact:

 

Mark Winnett

Phone:

 

+1 215 720 1298

Email:

 

mark@biotechleadership.com

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005694/en/

CONTACT

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • SETi’s Violeds Technology Solution to Support Delta Variant Spreading Prevention
  • Seoul Viosys Reports Record-High Second Quarter 2021 Results
  • Tiens Group Held an International Health Industry Forum
  • Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
  • Engrail Therapeutics 宣布扩展A轮融资至6400万美元